Alimera Sciences, Inc. (NASDAQ:ALIM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.
According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “
A number of other research firms have also recently issued reports on ALIM. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Alimera Sciences in a research report on Wednesday, November 22nd. Cowen Inc set a $3.00 price objective on shares of Alimera Sciences and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, ValuEngine upgraded shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a research report on Friday, October 20th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $3.38.
Alimera Sciences (NASDAQ ALIM) traded up $0.02 during midday trading on Monday, reaching $1.26. 44,200 shares of the company’s stock were exchanged, compared to its average volume of 380,739. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71. Alimera Sciences has a 52-week low of $1.04 and a 52-week high of $1.72.
Institutional investors and hedge funds have recently bought and sold shares of the company. KCG Holdings Inc. increased its position in shares of Alimera Sciences by 127.0% during the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 43,977 shares during the period. PNC Financial Services Group Inc. boosted its stake in Alimera Sciences by 24.3% during the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock worth $251,000 after acquiring an additional 35,200 shares in the last quarter. Stonepine Capital Management LLC boosted its stake in Alimera Sciences by 158.2% during the third quarter. Stonepine Capital Management LLC now owns 477,226 shares of the biopharmaceutical company’s stock worth $644,000 after acquiring an additional 292,399 shares in the last quarter. Finally, JW Asset Management LLC boosted its stake in Alimera Sciences by 15.6% during the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock worth $1,343,000 after acquiring an additional 130,000 shares in the last quarter. Institutional investors own 37.33% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://transcriptdaily.com/2017/11/27/alimera-sciences-inc-alim-cut-to-sell-at-zacks-investment-research.html.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.